- In February 2025, Edwards Lifesciences received expanded FDA approval for its SAPIEN 3 Ultra RESILIA transcatheter heart valve system for use in low-risk patients with severe aortic stenosis. The device features RESILIA tissue technology designed to reduce calcification and extend valve durability, supporting broader adoption in younger patient populations
- In November 2024, Abbott launched its TriClip Transcatheter Tricuspid Valve Repair System in Europe following CE Mark approval. The device provides a minimally invasive treatment for tricuspid regurgitation and builds upon the company’s MitraClip platform, representing a major innovation in treating previously underserved valve diseases
- In October 2024, Medtronic unveiled new clinical data at the TCT 2024 conference demonstrating the long-term safety and efficacy of its Evolut PRO+ TAVR system, particularly in bicuspid aortic valve patients. These findings support expanded indications and global market penetration of the platform
- In September 2024, Boston Scientific announced the commercial availability of its ACURATE neo2 Aortic Valve System in key European markets. The system is designed for improved sealing and ease of implantation, offering an alternative to current TAVR solutions and targeting a broader range of anatomical variations
